Caprotec Bioanalytics and Syngenta Announce Research Collaboration

Berlin, Germany, August 12, 2013 – caprotec bioanalytics GmbH and Syngenta International AG announced today a joint research agreement in which Syngenta will gain access to caprotec’s proprietary Capture Compound Mass Spectrometry (CCMS) technology. The companies will work together to profile the interactions of one of Syngenta’s novel active compounds with the proteome in its relevant plant biological system. caprotec’s platform allows an unbiased evaluation of the interactions of small molecules with protein mixtures in a targeted and directed manner, thereby facilitating the identification and elucidation of tractable targets as well as accelerating the development of promising leads.

Dr Jonathan Turner, CEO of caprotec, commented, “With proven applicability in the pharmaceutical and agrochemical areas, we are pleased to collaborate with Syngenta to further endorse the use of our unique platform in the challenging field of crop science.”

Under the terms of the agreement, Syngenta will cover the associated research costs. caprotec will also receive success-based milestone payments. Further financial details were not disclosed.

About caprotec bioanalytics GmbH:

caprotec bioanalytics GmbH is a Berlin-based biotech company focusing on the commercialization of its proprietary Capture Compound Mass Spectrometry (CCMS) technology. The core of the CCMS technology consists of small, tri-functional molecules called capture compounds (CCs). They enable a targeted isolation and identification of proteins directly from complex biological samples in solution. The technology can be used in any species or tissue, to access proteins in any compartment, from cell surface to nucleus. As the leading, most widely applicable, platform for the isolation and analysis of proteins from complex mixtures, the CCMS technology has enormous potential in the identification, optimization and development to market of bioactive small molecules and the development of protein biomarkers. The technology is protected by a broad patent portfolio. The company is supported by an international scientific advisory board including one Nobel Laureate.

For further information please contact:
caprotec bioanalytics GmbH
Corporate Communications
Tel.: +49 (0)30-6392-3990
[email protected]